Novartis, Edouard-Marcel Sandoz
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...
A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results